Analysis of validamycin as a potential antifungal compound against Candida albicans

Guirao Abad, José P.; Sánchez Fresneda, Ruth; Valentín, Eulogio; Argüelles, Juan Carlos; Martínez-Esparza Alvargonzález, María Concepción

Publication:
Analysis of validamycin as a potential antifungal compound against Candida albicans

dc.contributor.author	Guirao Abad, José P.
dc.contributor.author	Sánchez Fresneda, Ruth
dc.contributor.author	Valentín, Eulogio
dc.contributor.author	Argüelles, Juan Carlos
dc.contributor.author	Martínez-Esparza Alvargonzález, María Concepción
dc.contributor.department	Bioquímica y Biología Molecular B e Inmunología
dc.date.accessioned	2024-07-03T07:47:35Z
dc.date.available	2024-07-03T07:47:35Z
dc.date.issued	2013-12-12
dc.description	© 2013 Sociedad Española de Microbiología. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ This document is the Published version of a Published Work that appeared in final form in International Microbiology. To access the final edited and published work see https://doi.org/10.2436/20.1501.01.197
dc.description.abstract	Validamycin A has been successfully applied in the fight against phytopathogenic fungi. Here, the putative antifungal effect of this pseudooligosaccharide against the prevalent human pathogen Candida albicans was examined. Validamycin A acts as a potent competitive inhibitor of the cell-wall-linked acid trehalase (Atc1p). The estimated MIC50 for the C. albicans parental strain CEY.1 was 500 mg/l. The addition of doses below MIC50 to exponentially growing CEY.1 cells caused a slight reduction in cell growth. A concentration of 1 mg/ml was required to achieve a significant degree of cell killing. The compound was stable as evidenced by the increased reduction of cell growth with increasing incubation time. A homozygous atc1delta/atc1delta mutant lacking functional Atc1p activity showed greater resistance to the drug. The antifungal power of validamycin A was limited compared with the drastic lethal action caused by exposure to amphotericin B. The endogenous content of trehalose rose significantly upon validamycin and amphotericin B addition. Neither serum-induced hypha formation nor the level of myceliation recorded in macroscopic colonies were affected by exposure to validamycin A. Our results suggest that, although validamycin A cannot be considered a clinically useful antifungal against C. albicans, its mechanism of action and antifungal properties provide the basis for designing new, clinically interesting, antifungal-related compounds.	es
dc.format	application/pdf	es
dc.format.extent	9	es
dc.identifier.citation	International Microbiology, 2013, Vol. 16, N. 4, pp. 217-225
dc.identifier.doi	https://doi.org/10.2436/20.1501.01.197
dc.identifier.issn	Print: 1139-6709
dc.identifier.issn	Electronic: 1618-1905
dc.identifier.uri	http://hdl.handle.net/10201/142810
dc.language	eng	es
dc.publisher	Institut d’Estudis Catalans	es
dc.relation	The experimental work was supported by grant PI12/01797 (Ministerio de Economía y Competitividad, ISCIII, Spain). We are also indebted to the financial contract provided by Cespa Servicios Urbanos de Murcia, S.A.	es
dc.relation.publisherversion	https://revistes.iec.cat/index.php/IM/article/view/83098
dc.rights	info:eu-repo/semantics/openAccess	es
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 Internacional	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/	*
dc.subject	Candida albicans	es
dc.subject	Rhizoctonia solani	es
dc.subject	Validamycin A	es
dc.subject	Amphotericin B	es
dc.subject	Trehalose	es
dc.title	Analysis of validamycin as a potential antifungal compound against Candida albicans	es
dc.type	info:eu-repo/semantics/article	es
dspace.entity.type	Publication	es
relation.isAuthorOfPublication	79449fb4-f715-4255-a064-bfecc4b502de
relation.isAuthorOfPublication.latestForDiscovery	79449fb4-f715-4255-a064-bfecc4b502de